Table 3.

Serum levels of glycaemic and insulinemic biomarkers at baseline compartment of study and 8 weeks after the intervention in women with BBT who received BV supplementation (BV group) versus placebo juice consumers (control).

Variable	Baseline (n = 40)				8-weeks follow-up (n = 40)				Absolute treatment effect			Relative treatment effect
	n	Mean	S.D.	P	n	Mean	S.D.	P	Mean	95%CI	P c
Insulin (U/mL)
Control	39	0.38	0.33	N/A	39	0.50*	0.17	N/A	N/A	N/A	N/A	1.00
BV	35	0.49	0.43	0.09	35	0.51*	0.22	0.72	0.10	(-0.08-0.28)	0.26	0.81
C-peptide (ng/mL)
Control	40	2.27	1.06	N/A	40	2.97*	1.13	N/A	N/A	N/A	N/A	1.00
BV	40	2.56	1.12	0.23	40	3.42*	1.44	0.16	-0.15	(-0.62-0.32)	0.13	0.92
FBS (mg/dL) d
Control	40	92.22	14.73	N/A	40	87.85	12.14	N/A	N/A	N/A	N/A	1.00
BV	40	89.25	9.33	0.28	40	91.00	10.85	0.22	-6.12	(-12.7-0.50)	0.97	1.06
HOMA-IR e
Control	39	0.09	0.09	N/A	40	0.11	0.04	N/A	N/A	N/A	N/A	1.00
BV	39	0.10	0.09	0.34	37	0.11	0.06	0.19	0.01	(-0.03-0.06)	0.44	0.84
HOMB f
Control	39	13.30	49.87	N/A	39	9.69*	6.54	N/A	N/A	N/A	N/A	1.00
BV	36	10.26	15.86	0.05	36	9.80*	9.49	0.05	375	(21-730)	0.86	1.44
QUIKI g
Control	39	0.72	0.15	N/A	40	0.62*	0.06	N/A	N/A	N/A	N/A	1.00
BV	38	0.67	0.13	0.15	37	0.62*	0.07	0.94	-0.04	(-0.11-0.02)	0.29	0.94
G:I ratio h
Control	39	345.08	219	N/A	39	186.01*	49.14	N/A	N/A	N/A	N/A	1.00
BV	36	271	194	0.11	36	185.23*	79.07	0.92	0.15	(-0.05-0.35)	0.28	0.78

All data are expressed in geometric mean ± S.D.. N/A: not applied to this model.

^a Paired t-test was performed to compare within changes in intervention group during the study.

^b  Independent sample t-test was performed between group.

^c  Repeated measure of ANOVA was carried out in the main effect of model.

^e  Homeostatic model assessment.

^f  Assessment of B-cell functionality.

^g  quantitative insulin sensitivity check index glucose to insulin ratio.

^h Glucose to insulin ratio.